• Mashup Score: 1
    Instagram - 9 month(s) ago

    Palo Alto, Calif. – August 22, 2023 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announce the U.S. Food and Drug Administration (FDA) Circulatory Systems Devices Panel of the Medical Devices Advisory Committee met to discuss the pre-market approval application (PMA) for the Paradise™ Ultrasound Renal Denervation (RDN) system, indicated to reduce blood pressure in patients with hypertension. The overall vote from the committee was

    Tweet Tweets with this article
    • Recor Medical and Otsuka Medical Devices Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System for the Treatment of Hypertension. Read more... https://t.co/EWH8pDGdqi https://t.co/6bD2vOg1QS

  • Mashup Score: 1

    Ultrasound Denervation Product

    Tweet Tweets with this article
    • Proud that S. Maria Goretti Hospital in Latina is the 1st institution in Italy to perform a case of renal ultrasound denervation with the Paradise device, masterfully performed by Prof. Francesco Versaci and Dr. Iginio Colaiori https://t.co/hhboKDZdwf @ReCorMedical @RADIANCE_HTN https://t.co/dDycmVt8wf

  • Mashup Score: 0
    Clinical Results - 3 year(s) ago

    Paradise Renal Denervation System Clinical Evidence Azizi et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single- blind, sham-controlled trial. Lancet. 2021. In press Azizi et al. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular…

    Tweet Tweets with this article
    • RT @ReCorMedical: Thank you for joining us #ACC21 and #EuroPCR! Learn more about RADIANCE-HTN TRIO: https://t.co/KwzIM8v0l1 #RenalDenerva…